NPM1 and acute myeloid leukemia: Finally, comparative studies have evaluated VEN–HMA regimens versus intensive chemotherapy in patients aged ≥60 years with NPM1-mutated AML, showing that low-intensity strategies are non-inferior—and potentially superior—in selected subgroups [17].